MONROVIA, CA, March 27, 2012 (Press-News.org) Alexander Meissner, Assistant Professor at Harvard University will give a keynote presentation on ¡°DNA Methylation Dynamics in Development and Stem Cells¡± at the 2nd Epigenetics in Drug Discovery Conference taking place on May 30-31, 2012 in Boston, MA.
Cytosine methylation in mammals is an epigenetic modification that is largely restricted to CpG dinucleotides and serves multiple critical functions including stable repression of target promoters, maintaining genomic integrity, establishing parent-specific imprinting patterns, and silencing endogenous retrotransposon activity. In somatic tissues, CpG methylation exhibits global patterns based on relative CpG density: it is unmethylated in localized CpG islands at housekeeping or developmental promoters, and hypermethylated at non-regulatory CpGs distributed elsewhere in the genome. This landscape is relatively static across all somatic tissues that have been examined to date on a genome scale, where the majority of methylated CpGs are pre-established and inherited through cell divisions.
Generally, only a small fraction of CpGs switch their methylation levels as part of an orchestrated regulatory event. By contrast, DNA methylation is much more dynamic during mouse germ-cell and pre-implantation development. Alex Meissner¡¯s presentation will provide recent insights gained through genome-scale mapping of DNA methylation in human pluripotent stem cells and murine development.
Alex Meissner trained in Rudolf Jaenisch¡¯s laboratory at the Whitehead Institute, before he joined Harvard University as assistant professor in the department of stem cell and regenerative biology in 2008. He is also a member of the Harvard Stem Cell Institute and a senior associate member of the Broad Institute. Working with his colleagues at the Broad Institute, Alex is developing and applying high-throughput bisulfite sequencing technologies for DNA methylation analysis. This should ultimately lead to creating reference epigenomes ¨C maps of what happens outside the DNA sequence -- for many cell types, with the goal of better understanding normal and diseased cellular states.
He is co-directing the NIH Reference Epigenome Mapping Center at the Broad Institute. Complementing his work on epigenomics, his lab has a major interest in cell states and how they can be altered through ectopic transcription factors. He has led several of the early studies in the induced pluripotent stem (iPS) field while in the Jaenisch lab. His lab has since then made notable contributions to the understanding of the process and he was recently named a Pew Scholar in the Biomedical Sciences.
GTC¡¯s 2nd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, technologies and diagnostics for epigenetics drug discovery. Some key discussions around epigenetics drug discovery at the conference include the role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc., and cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Cellzome, RaNA Therapeutics, Pfizer, Harvard, and Massachusetts Institute of Technology.
The conference is part of the Omics Evolution Summit, which includes 6 co-located conferences and a Clinical Sequencing Workshop on May 29th. Register for the entire summit and have access to the all of the following conferences:
2nd Genomic & Proteomic Drug Discovery Conference
3rd RNAi Research & Therapeutics Conference
7th Protein Kinases in Drug Discovery Conference
2nd Next Generation Sequencing Conference
Genome-wide Partnering and Deal Making Conference
For more information, please visit http://www.gtcbio.com
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
Alexander Meissner to speak at 2nd Epigenetics Drug Discovery conference May 30-31, 2012 Boston, MA
Alexander Meissner, Assistant Professor at Harvard University, will give a keynote presentation at the 2nd Epigenetics in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)
2012-03-27
ELSE PRESS RELEASES FROM THIS DATE:
Genetic risk and stressful early infancy join to increase risk for schizophrenia
2012-03-27
Working with genetically engineered mice and the genomes of thousands of people with schizophrenia, researchers at Johns Hopkins say they now better understand how both nature and nurture can affect one's risks for schizophrenia and abnormal brain development in general.
The researchers reported in the March 2 issue of Cell that defects in a schizophrenia-risk genes and environmental stress right after birth together can lead to abnormal brain development and raise the likelihood of developing schizophrenia by nearly one and half times.
"Our study suggests that if ...
OBX Outfitters Publishes OBX Spring Training Online Resource for Outer Banks Running, Outdoor Events
2012-03-27
Casual apparel and activewear company OBX Outfitters is providing a free online resource for Outer Banks groups and organizations to publicize their springtime charity running and other outdoor events, http://www.obxspringtraining.com.
Additionally, OBX Outfitters is offering a 25% off its North Carolina-Made Find Your Stride activewear for runners and supporters of the events.
"We're committed to helping community organizations in the Outer Banks, and providing free publicity and discounts on our running shirts is just one small way we can make a contribution," ...
CDAA Web Company Announces New Client: William Buck
2012-03-27
CDAA Pty Ltd, an Australian based Certified Web Company, today announced the signing of its newest client, William Buck, a leading firm of Chartered Accountants and advisors in Australia and New Zealand.
CDAA is providing graphic design, web design, web development, web hosting and email marketing services to William Buck to help increase its brand visibility, website traffic and build new client relationships.
"We are partnering with CDAA, a leading-edge Web Company, to design and develop our new website. With CDAA we aim to ensure that our online image is ...
More energy efficient transistors through quantum tunneling
2012-03-27
Researchers at the University of Notre Dame and Pennsylvania State University have announced breakthroughs in the development of tunneling field effect transistors (TFETs), a semiconductor technology that takes advantage of the quirky behavior of electrons at the quantum level.
Transistors are the building blocks of the electronic devices that power the digital world, and much of the growth in computing power over the past 40 years has been made possible by increases in the number of transistors that can be packed onto silicon chips.
But that growth, if left to current ...
Essential tremor patient regains independence following surgery
2012-03-27
CHICAGO – For nearly 30 years, Tom Rogers' left hand would shake when he tried to use it, making even simple tasks such as drinking a glass of water, writing a check, or making a sandwich challenging. The tremor eventually became so disruptive that he lost use of his dominant hand. Rogers sought care and learned that his tremor was a symptom of Parkinson's disease, yet felt he was suffering from something different.
"I was familiar with Parkinson's because my father had it and I knew this wasn't the same," said Rogers, a 66-year-old retired truck driver who resides in ...
Boast Capital Announces SR&ED Seminar at Innovate Calgary
2012-03-27
Boast Capital announces SR&ED Seminar at Innovate Calgary on Wednesday, April 4th from 7:30-9:30am to discuss changes to the SR&ED program arising from the new federal budget.
Canada is one of the most generous countries in funding research, innovation, and experimentation, providing approximately $7 billion annually to over 30,000 companies. Over $4.5 billion of this funding pool is provided under the SR&ED program.
As a part of the Federal Budget on March 29th, 2012, significant changes are expected to the SR&ED program. This seminar will provide ...
Human noise has ripple effects on plants
2012-03-27
A growing body of research shows that birds and other animals change their behavior in response to human noise, such as the din of traffic or the hum of machinery.
But human clamor doesn't just affect animals.
Because many animals also pollinate plants or eat or disperse their seeds, human noise can have ripple effects on plants, too, finds a new study reported in the March 21, 2012, issue of the journal Proceedings of the Royal Society B.
In cases where noise has ripple effects on long-lived plants like trees, the consequences could last for decades, even after ...
Cable TV Company to Launch Telescoping Technology in Decatur, Illinois
2012-03-27
Bruce Wilson of Comcast Spotlight announced today a new interactive cable TV service called "Telescoping" that is being launched in April in the Decatur Zone that will empower advertisers to better explain their products and services in ways that a thirty or sixty second commercial spot cannot. He explained that, "Telescoping is an interactive overlay on a TV commercial that allows advertisers to free themselves from the restrictions of a thirty second commercial and extend messaging about their product or service on demand."
For some time now Comcast ...
Does the brain 'remember' antidepressants?
2012-03-27
Individuals with major depressive disorder (MDD) often undergo multiple courses of antidepressant treatment during their lives. This is because the disorder can recur despite treatment and because finding the right medication for a specific individual can take time.
While the relationship between prior treatment and the brain's response to subsequent treatment is unknown, a new study by UCLA researchers suggests that how the brain responds to antidepressant medication may be influenced by its remembering of past antidepressant exposure.
Interestingly, the researchers ...
Top priorities in biodiversity science agreed
2012-03-27
Concluding a four-year global consultation, international experts have agreed on key efforts needed to reduce the on-going loss of biodiversity and associated ecosystem services.
On Day 2 of the Planet under Pressure conference in London (planetunderpressure2012.net) March 27, leaders of the global biodiversity research programme DIVERSITAS described the urgent need to better understand the "5 Ws" -- who, what, where, when and why -- of biodiversity loss, and how humanity might mitigate it.
Human well-being depends on ecosystems like forests and coral reefs continuing ...
LAST 30 PRESS RELEASES:
How rice plants tell head from toe during early growth
Scientists design solar-responsive biochar that accelerates environmental cleanup
Construction of a localized immune niche via supramolecular hydrogel vaccine to elicit durable and enhanced immunity against infectious diseases
Deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for targeted cancer therapy
DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer
Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model
Neg-entropy is the true drug target for chronic diseases
Oxygen-boosted dual-section microneedle patch for enhanced drug penetration and improved photodynamic and anti-inflammatory therapy in psoriasis
Early TB treatment reduced deaths from sepsis among people with HIV
Palmitoylation of Tfr1 enhances platelet ferroptosis and liver injury in heat stroke
Structure-guided design of picomolar-level macrocyclic TRPC5 channel inhibitors with antidepressant activity
Therapeutic drug monitoring of biologics in inflammatory bowel disease: An evidence-based multidisciplinary guidelines
New global review reveals integrating finance, technology, and governance is key to equitable climate action
New study reveals cyanobacteria may help spread antibiotic resistance in estuarine ecosystems
Around the world, children’s cooperative behaviors and norms converge toward community-specific norms in middle childhood, Boston College researchers report
How cultural norms shape childhood development
University of Phoenix research finds AI-integrated coursework strengthens student learning and career skills
Next generation genetics technology developed to counter the rise of antibiotic resistance
Ochsner Health hospitals named Best-in-State 2026
A new window into hemodialysis: How optical sensors could make treatment safer
High-dose therapy had lasting benefits for infants with stroke before or soon after birth
‘Energy efficiency’ key to mountain birds adapting to changing environmental conditions
Scientists now know why ovarian cancer spreads so rapidly in the abdomen
USF Health launches nation’s first fully integrated institute for voice, hearing and swallowing care and research
Why rethinking wellness could help students and teachers thrive
Seabirds ingest large quantities of pollutants, some of which have been banned for decades
When Earth’s magnetic field took its time flipping
Americans prefer to screen for cervical cancer in-clinic vs. at home
Rice lab to help develop bioprinted kidneys as part of ARPA-H PRINT program award
Researchers discover ABCA1 protein’s role in releasing molecular brakes on solid tumor immunotherapy
[Press-News.org] Alexander Meissner to speak at 2nd Epigenetics Drug Discovery conference May 30-31, 2012 Boston, MAAlexander Meissner, Assistant Professor at Harvard University, will give a keynote presentation at the 2nd Epigenetics in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)